PELF is More Active than FAMTX in Metastatic Gastric Carcinoma (MGC)

Li Liu, MD

University of Pennsylvania Cancer
Ultima Vez Modificado: 14 de mayo del 2001

Share article


Presenter: G. Cocconi
Affiliation: Italian Oncology Group for Clinical Research (GOIRC), Parma, Italy

Background:

    Most patients with gastric cancer in the United States are found at the time of diagnosis to have advanced disease. The prognosis of these patients is extremely poor. Various treatment regimens have been explored.

Materials and Methods:

  • A total of 195 patients with metastatic gastric carcinoma (MGC) were included in this randomized study Patients received 6 cycles of either PELF (Cisplatin, epirubicin, Leucovorin, and 5-FU) (98 patients) or FAMTX (methotrexate, 5-FU, and adriamycin) (97 patients).

Results:

  • PELF treated patients achieved much higher response rate (39% vs. 22%, p=0.009).
  • The one-year and two-year survival rates were not significantly higher statistically in the PELF group than FAMTX group (30.8% vs 22.4% and 15.7% vs 9.5%, p=0.19).
  • PELF was associated with more significant nausea/vomiting and diarrhea.
  • Mucositis was significantly more severe in FAMTX group.

Authors' Conclusions

  • PELF appeared to be more significantly active in patients with MGC.
  • Survival was better at one and two years with PELF, but not statistically significant.
  • The two treatment regimens were tolerable, although different in spectrum. FAMTX should no longer be considered as an active new-generation regimen for patients with MGC.

Clinical/Scientific Implications:

  • PELF deserves further study in adjuvant settings.
  • Regimens involving biochemical modulation of 5-FU such as the FAMTX and PELF regimens are one major focus of investigation in patients with MGC. The development of new active agents is equally important.

ASCO Abstract 501

Saturday | Sunday | Monday | Tuesday

OncoLink ASCO 2001 coverage is provided by an unrestricted educational grant from Amgen


News
ASCO: Dabrafenib/Trametinib Active in Metastatic Melanoma

May 18, 2012 - For patients with V600 BRAF-mutant solid tumors, treatment with the oral BRAF inhibitor dabrafenib and the oral MEK 1/2 inhibitor trametinib is tolerated and has clinical activity in BRAF inhibitor-naive metastatic melanoma, according to a study released May 16 in advance of presentation at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información